![Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing](https://cdn.cancerletter.com/media/2022/04/29132656/48-17-MTD-4x3-1.jpg)
![Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing](https://cdn.cancerletter.com/media/2022/04/29132656/48-17-MTD-4x3-1.jpg)
Cover Story
Clinical
By Alice Tracey
For decades, pinpointing the highest dose of a drug that cancer patients could tolerate was the first step investigators were required to take before moving into phase II and III clinical trials.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How a Georgetown med school student found her calling in surgery, law, and health equity
- Georgetown-MedStar: Patients with cancer can rely on our lawyers to fight legal issues that harm health